GAMMA Investing LLC Acquires 1,562,396 Shares of Pfizer Inc. (NYSE:PFE)

GAMMA Investing LLC boosted its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4,183.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,599,742 shares of the biopharmaceutical company's stock after acquiring an additional 1,562,396 shares during the period. GAMMA Investing LLC's holdings in Pfizer were worth $40,537,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PFE. AdvisorNet Financial Inc boosted its holdings in shares of Pfizer by 7.7% during the 1st quarter. AdvisorNet Financial Inc now owns 46,612 shares of the biopharmaceutical company's stock worth $1,181,000 after buying an additional 3,341 shares in the last quarter. Nexus Investment Management ULC boosted its holdings in shares of Pfizer by 5.9% during the 1st quarter. Nexus Investment Management ULC now owns 866,837 shares of the biopharmaceutical company's stock worth $21,966,000 after buying an additional 48,550 shares in the last quarter. Exeter Financial LLC boosted its holdings in shares of Pfizer by 88.5% during the 1st quarter. Exeter Financial LLC now owns 28,195 shares of the biopharmaceutical company's stock worth $714,000 after buying an additional 13,239 shares in the last quarter. Quent Capital LLC boosted its holdings in shares of Pfizer by 15.1% during the 1st quarter. Quent Capital LLC now owns 12,878 shares of the biopharmaceutical company's stock worth $326,000 after buying an additional 1,694 shares in the last quarter. Finally, Legacy Private Trust Co. boosted its holdings in shares of Pfizer by 4.4% during the 1st quarter. Legacy Private Trust Co. now owns 14,366 shares of the biopharmaceutical company's stock worth $364,000 after buying an additional 600 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 1.2%

Shares of NYSE PFE traded down $0.29 during trading on Thursday, hitting $23.11. The stock had a trading volume of 33,167,122 shares, compared to its average volume of 40,928,184. The firm has a fifty day moving average of $23.02 and a two-hundred day moving average of $25.02. The company has a market capitalization of $131.36 billion, a PE ratio of 16.39, a PEG ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.82 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.44%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's payout ratio is 124.64%.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Guggenheim restated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.